Future use of selective estrogen receptor modulators and aromatase inhibitors

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4402s-4410s

  Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; ARZOXIFENE; DIENESTROL; DIETHYLSTILBESTROL; DROLOXIFENE; ETHINYLESTRADIOL; EXEMESTANE; FORMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MIPROXIFENE PHOSPHATE; PIPENDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; ZK 191703;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; HUMAN; ISOMERISM; PRIORITY JOURNAL; TARGET CELL;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; ESTROGENS; FEMALE; FORECASTING; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0035667428     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Influence of synthetic oestrogens upon advanced malignant disease
2. Synthetic oestrogens in mammary cancer
3. Randomized trial of estrogen versus tamoxifen therapy for advanced breast cancer
4. Randomised trial of diethylstilboestrol versus tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis
5. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment for advanced breast cancer
6. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474
7. New endocrine therapies for breast cancer
8. Safety and efficacy results of a randomised trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node positive breast cancer
9. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
10. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce conformational changes in the estrogen receptor
11. Molecular mechanism of action at oestrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
12. Preliminary results of a randomised double-blind Phase II study of the selective oestrogen receptor modulator (SERM) arzoxifene (AZ) in patients with locally advanced or metastatic breast cancer
13. ICI 182780, a new antioestrogen with clinical potential
14. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
15. Comparison of efficacy and tolerability of fulvestrant (Faslodex) with anastrozole (Arimidex) in post-menopausal (PM) women with advanced breast cancer (ABC): Preliminary results
16. A double-blind randomised trial comparing the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC)
17. Preliminary trial of aminoglutethimide in breast cancer
18. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature Phase III trials
19. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double blind randomized trial showing a dose effect and tolerability compared with megestrol acetate
20. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a Phase III randomized double-blind trial
21. Preliminary results of two multicentre trials comparing the efficacy and tolerability of Arimidex (anastrozole) and tamoxifen (TAM) in post-menopausal women with advanced breast cancer (ABC)
22. rd San Antonio Breast Cancer Symposium
23. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the International Letrozole Breast Cancer Group
24. Promising activity and safety of exemestane (E) as first line hormonal therapy (HT) in metastatic breast cancer (MBC) patients: Final results of an EORTC randomised Phase II trial
25. Tamoxifen for early breast cancer: Overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBTCG)
26. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
27. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
28. Dissociation between steroid receptor expression and cell proliferation in the human breast
29. Abnormal regulation of the oestrogen receptor in benign breast lesions
30. Estrogen therapy in the management of advanced breast carcinoma
31. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
32. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro
33. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
34. Hormone-induced tumor flare
35. Inhibition of tamoxifen stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
36. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
37. The primary use of endocrine therapies
38. Effect of Lyndiol, an oral contraceptive, on breast cancer
39. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer
40. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
41. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
42. Randomised double blind Phase 2 study of a selective estrogen receptor modulator (SERM) in patients with locally advanced or metastatic breast cancer (LAMBC)
43. Phase I study of a third generation SERM LY353381.HCL in metastatic breast cancer
44. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A Phase II trial
45. Formestane (FOR) a steroidal aromatase inhibitor (SAI) after failure of nonsteroidal aromatase inhibitors (NSAI) (anastrozole: ANZ and letrozole:LTZ): Is a clinical benefit still possible?